Relmada Therapeutics Q3 EPS $(0.73) Beats $(0.91) Estimate
Portfolio Pulse from bharat@benzinga.com
Relmada Therapeutics reported Q3 losses of $(0.73) per share, beating the analyst consensus estimate of $(0.91) by 19.78 percent. This represents a 44.27 percent increase over losses from the same period last year.
November 08, 2023 | 10:40 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Relmada Therapeutics reported better than expected Q3 losses, which could positively impact the stock in the short term.
Relmada Therapeutics reported a smaller loss than expected for Q3, which is generally seen as a positive sign by investors. This could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100